Optimal management of taxane acute pain syndrome not clear
the ONA take:
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome (TAPS) remains poorly researched with few studies have evaluated its optimal management, according to a systematic review published online ahead of print in the journal Supportive Care in Cancer.
TAPS is characterized by myalgias and arthralgias beginning 1 to 3 days and lasting 5 to 7 days after taxane-based chemotherapy.
Although it is known to negatively impact patients’ quality of life, the optimal management of TAPS is unclear.
Therefore, researchers at The Ottawa Hospital and University of Ottawa in Ontario, Canada, conducted a systematic review of treatment strategies for TAPS across all tumor sites.
Results showed that neither glutathione nor glutamine were superior to placebo for TAPS. Researchers found that amifostine, a cytoprotective adjuvant used in cancer chemotherapy and radiotherapy, reduced pain in 36% of patients, while gabapentin reduced taxane-induced arthralgias and myalgias in 90% of patients.
“If the management of patients is to be improved, more prospective trials are needed,” the authors conclude.
Despite its prevalence in patients receiving taxane-based chemotherapies, taxane acute pain syndrome remains poorly researched.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|